While maximal safe resection represents the first management step for any patient with a newly diagnosed glioblastoma,1 about 20–30% of individuals initially present with imaging findings deemed as not meaningfully resectable by the treating neurosurgeon due to proximity to functional brain areas.2 In these cases, biopsy for neuropathological confirmation is typically scheduled to guide further non-surgical treatment; however, such patients do not experience the presumed oncological benefits from cytoreductive surgery.
Karschnia et al. (Mon,) studied this question.